ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Reply to Y. Xia et al.
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
- Comment on
Authors and funding
5 authors.
Sebastian BauerSebastian Bauer, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; Jonathan A. Fletcher, MD, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Daniel Rauh, PhD, Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany, Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany; Johanna Falkenhorst, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; and Thomas Mühlenberg, PhD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-5949-8120
Jonathan A FletcherSebastian Bauer, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; Jonathan A. Fletcher, MD, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Daniel Rauh, PhD, Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany, Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany; Johanna Falkenhorst, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; and Thomas Mühlenberg, PhD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-5109-2588
Daniel RauhSebastian Bauer, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; Jonathan A. Fletcher, MD, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Daniel Rauh, PhD, Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany, Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany; Johanna Falkenhorst, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; and Thomas Mühlenberg, PhD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-1970-7642
Johanna FalkenhorstSebastian Bauer, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; Jonathan A. Fletcher, MD, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Daniel Rauh, PhD, Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany, Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany; Johanna Falkenhorst, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; and Thomas Mühlenberg, PhD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-4738-7121
Thomas MühlenbergSebastian Bauer, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; Jonathan A. Fletcher, MD, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Daniel Rauh, PhD, Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany, Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany; Johanna Falkenhorst, MD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany; and Thomas Mühlenberg, PhD, Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany, DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-2078-8857
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
38976807What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.